Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular ...
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
Hosted on MSN1d
Some Cancer Genes Could Play A Role In Protecting YouNew research suggests a genetic mutation previously believed to promote esophageal cancer might actually play a protective ...
Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.
An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback